Table III.
Twenty-four week change in asthma symptoms, lung function, and sinus symptoms in children (ages 6-17) treated with mometasone versus placebo.
| N | Change from randomization (SE) |
Difference in change from randomization (95% CI) |
P-value | ||
|---|---|---|---|---|---|
| Mometasone | Placebo | Mometasone - Placebo | |||
| Asthma Symptom Utility Index | 126 | 0.04 (0.02) | 0.1 (0.02) | -0.06 (-0.13 ,0.01) | 0.07 |
| Childhood health survey for asthma | |||||
| Physical health | 123 | 6.37 (1.63) | 7.33 (1.59) | -0.95 (-5.45 ,3.55) | 0.68 |
| Activities (child) | 125 | 7.41 (2.03) | 5.95 (2.38) | 1.45 (-4.74 ,7.65) | 0.64 |
| Activities (family) | 125 | 2.09 (1.74) | 5.35 (1.43) | -3.26 (-7.72 ,1.20) | 0.15 |
| Emotional health (child) | 125 | 3.87 (2.83) | 7.35 (2.46) | -3.48 (-10.91 ,3.94) | 0.36 |
| Emotional health (family) | 123 | 4.01 (1.61) | 3.26 (1.55) | 0.76 (-3.66 ,5.18) | 0.74 |
| Lung function | |||||
| Pre-bronchodilator FEV1 (% predicted) | 127 | 2.62 (1.68) | -0.83 (1.1) | 3.45 (-0.52 ,7.42) | 0.09 |
| Pre-bronchodilator FVC (% predicted) | 127 | 2.1 (1.24) | -0.34 (0.92) | 2.44 (-0.60 ,5.48) | 0.12 |
| FEV1/FVC | 127 | 0.007 (0.009) | -0.007 (0.006) | 0.013 (-0.009 ,0.035) | 0.23 |
| FeNO (ppb)* | 123 | 10.92 (5.34) | 5.65 (2.89) | 5.28 (-6.72, 17.28) | 0.39 |
| Sinus symptoms | |||||
| Sinus Symptom Score | 127 | -7.38 (1.38) | -7.38 (1.43) | -0.004 (-3.94 ,3.93) | > 0.99 |
| SN-5 | 126 | -0.76 (0.12) | -0.98 (0.14) | 0.22 (-0.14, 0.59) | 0.22 |
*
FeNO was measured at baseline and at 24 weeks.
N = number of participants evaluable at 24 weeks; CI = confidence interval; Δ = change. I